DBV Technologies Begins Pivotal Peanut Allergy Study, Aims for 2026 FDA Submission.
DBV Technologies (NASDAQ:DBVT) is one of the best-performing NASDAQ stocks according to analysts.
Dbv Technologies S.a. (DBVT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,461,425 | $14,614,250 | 0.11% | |
| 2. | Vivo Capital Albert Cha And Frank Kung | 1,054,506 | $10,545,060 | 0.85% | |
| 3. | BioImpact Capital Mpm Capital | 1,054,504 | $10,545,040 | 1.73% | |
| 4. | Octagon Capital Advisors Ting Jia | 1,018,021 | $10,180,210 | 1.54% | |
| 5. | Yiheng Capital Jonathan Guo | 656,309 | $6,563,090 | 0.97% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.83 | 17,094 | $14,188.02 | 17,094 | 2024-03-08 | Filing | |
| $0.89 | 1,825 | $1,624.25 | 1,825 | 2024-02-06 | Filing | |
| $1.52 | 12,000 | $18,240.00 | 12,000 | 2023-08-25 | Filing | |
| $1.62 | 15,000 | $24,300.00 | 20,000 | 2023-08-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.77 | 1,624 | $4,498.48 | 101,529 | 2025-11-21 | Filing | |
| $2.88 | 6,496 | $18,708.48 | 103,153 | 2025-11-20 | Filing | |
| $2.22 | 464 | $1,030.08 | 109,649 | 2025-07-29 | Filing | |
| $1.84 | 397 | $730.48 | 110,113 | 2025-05-22 | Filing | |
| $0.85 | 600 | $510.00 | 110,510 | 2025-01-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 51,920 | $519,200 | 0% | |
| 2. | 37,095 | $370,950 | 0.04% | |
| 3. | 30,005 | $300,050 | 0% | |
| 4. | 25,000 | $250,000 | 0.02% | |
| 5. | 16,682 | $166,820 | 0% |
News See All
12 Best Performing NASDAQ Stocks According to Analysts
On July 3, Dan Ives, the Global Head of Tech Research at Wedbush, appeared on CNBC to suggest that AI will fuel a multi-year tech rally. Ives stated that he believes they are only at the beginning of...
Goldman Sachs Analyst Reinstates Sell Rating on DBV Technologies Amid VP Treatment Risks
On May 28, Goldman Sachs analyst Rajan Sharma reinstated his sell rating on DBV Technologies S.A. (NASDAQ:DBVT) and set the price target at $7.25.
Why These 15 Healthcare Stocks Are Surging in 2025
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year.
DBV Technologies S.A. (NASDAQ:DBVT) Q2 2024 Earnings Call Transcript
Operator: Welcome to the DBV Second Quarter Financial Results and Business Update Conference Call. All participants will be in a listen-only mode.
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript
Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.
DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript
Operator: Welcome to the DBV's Third Quarter Financial Results and Business and Regulatory Update Conference Call. [Operator Instructions] Please note this event is being recorded.
DBV Technologies S.A. (NASDAQ:DBVT) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the DBV Technologies Second Quarter Financial Results Conference Call. My name is Vaishnavi, and I am the operator for this call.
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2022 Earnings Call Transcript
Operator: Good day, and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call. Please note this event is being recorded. I would now like to turn the conference over to Ms.
5 Best Medical Stocks Under $10
In this article, we will be looking at the 5 best medical stocks under $10.
Hedge Fund Resource Center Billionaire Hedge Funds
